Randomized Comparison of Different Thienopyridine Loading Strategies in Patients Undergoing Elective Coronary Intervention: The ExcelsiorLOAD Trial

JACC: Cardiovascular Interventions

Volumn 9, Issue 3, 2016, Pages 219-227

  Hochholzer, Willibald ^a   Amann, Michael ^a   Titov, Alexander ^a   Younas, Iris ^a   Löffelhardt, Nikolaus ^a   Riede, Florian ^a   Potocnik, Clemens ^a   Stratz, Christian ^a   Hauschke, Dieter ^b   Trenk, Dietmar ^a   Neumann, Franz Josef ^a   Valina, Christian M ^a  

^a UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

clopidogrel; nonresponder; percutaneous coronary intervention; platelet reactivity; prasugrel

Indexed keywords

CLOPIDOGREL; PRASUGREL; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

AGED; ANTICOAGULATION; ARTICLE; BLEEDING; DRUG SAFETY; FEMALE; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION; ANALOGS AND DERIVATIVES; CONTROLLED STUDY; DRUG ADMINISTRATION; DRUG EFFECTS; MIDDLE AGED; PREMEDICATION; THROMBOCYTE; THROMBOCYTE ACTIVATION;

AGED; BLOOD PLATELETS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PRASUGREL HYDROCHLORIDE; PREMEDICATION; PROSPECTIVE STUDIES; TICLOPIDINE;

EID: 84953265359     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2015.10.036     Document Type: Article

References (39)

1. 1 Hochholzer, W., Trenk, D., Bestehorn, H.P., et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 48 (2006), 1742–1750.
2. 2 Sibbing, D., Braun, S., Morath, T., et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 53 (2009), 849–856.
3. 3 Tantry, U.S., Bonello, L., Aradi, D., et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 62 (2013), 2261–2273.
4. 4 Franchi, F., Angiolillo, D.J., Novel antiplatelet agents in acute coronary syndrome. Nat Rev Cardiol 12 (2015), 30–47.
5. 5 Levine, G.N., Bates, E.R., Blankenship, J.C., et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 58 (2011), e44–e122.
6. 6 Windecker, S., Kolh, P., Alfonso, F., et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35 (2014), 2541–2619.
7. 7 Di Sciascio, G., Patti, G., Pasceri, V., Gatto, L., Colonna, G., Montinaro, A., Effectiveness of in-laboratory high-dose clopidogrel loading versus routine pre-load in patients undergoing percutaneous coronary intervention: results of the ARMYDA-5 PRELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial. J Am Coll Cardiol 56 (2010), 550–557.
8. 8 Widimsky, P., Motovska, Z., Simek, S., et al. Clopidogrel pre-treatment in stable angina: for all patients > 6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8. Eur Heart J 29 (2008), 1495–1503.
9. 9 Bhatt, D.L., Stone, G.W., Mahaffey, K.W., et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 368 (2013), 1303–1313.
10. 10 Steinhubl, S.R., Berger, P.B., Mann, J.T. 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288 (2002), 2411–2420.
11. 11 Bellemain-Appaix, A., O'Connor, S.A., Silvain, J., et al. Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. JAMA 308 (2012), 2507–2516.
12. 12 Capodanno, D., Angiolillo, D.J., Pretreatment with antiplatelet drugs in invasively managed patients with coronary artery disease in the contemporary era: review of the evidence and practice guidelines. Circ Cardiovasc Interv, 8, 2015, e002301.
13. 13 Collet, J.P., Silvain, J., Bellemain-Appaix, A., Montalescot, G., Pretreatment with P2Y12 inhibitors in non-ST-segment-elevation acute coronary syndrome: an outdated and harmful strategy. Circulation 130 (2014), 1904–1914 discussion 1914.
14. 14 Montalescot, G., Sechtem, U., Achenbach, S., et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 34 (2013), 2949–3003.
15. 15 Roffi, M., Patrono, C., Collet, J.P., et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J, 2015 Aug 29 [E-pub ahead of print].
16. 16 Hochholzer, W., Trenk, D., Frundi, D., et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 111 (2005), 2560–2564.
17. 17 Ferreiro, J.L., Ueno, M., Angiolillo, D.J., Cangrelor: a review on its mechanism of action and clinical development. Expert Rev Cardiovasc Ther 7 (2009), 1195–1201.
18. 18 Angiolillo, D.J., Schneider, D.J., Bhatt, D.L., et al. Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. J Thromb Thrombolysis 34 (2012), 44–55.
19. 19 Michelson, A.D., Frelinger, A.L. 3rd, Braunwald, E., et al. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J 30 (2009), 1753–1763.
20. 20 Jernberg, T., Payne, C.D., Winters, K.J., et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 27 (2006), 1166–1173.
21. 21 Thygesen, K., Alpert, J.S., Jaffe, A.S., Simoons, M.L., Chaitman, B.R., White, H.D., Third universal definition of myocardial infarction. Eur Heart J 33 (2012), 2551–2567.
22. 22 Mehran, R., Rao, S.V., Bhatt, D.L., et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 123 (2011), 2736–2747.
23. 23 Bernlochner, I., Mayer, K., Morath, T., et al. Antiplatelet efficacy of prasugrel in patients with high on-clopidogrel treatment platelet reactivity and a history of coronary stenting. Thromb Haemost 109 (2013), 517–524.
24. 24 Sibbing, D., Schulz, S., Braun, S., et al. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost 8 (2010), 250–256.
25. 25 Rollini, F., Franchi, F., Angiolillo, D.J., Switching P2Y12-receptor inhibitors in patients with coronary artery disease. Nat Rev Cardiol 3 (2016), 11–27.
26. 26 Zeymer, U., Mochmann, H.C., Mark, B., et al. Double-blind, randomized, prospective comparison of loading doses of 600 mg clopidogrel versus 60 mg prasugrel in patients with acute ST-segment elevation myocardial infarction scheduled for primary percutaneous intervention: the ETAMI trial (early thienopyridine treatment to improve primary PCI in patients with acute myocardial infarction). J Am Coll Cardiol Intv 8 (2015), 147–154.
27. 27 Jakubowski, J.A., Winters, K.J., Naganuma, H., Wallentin, L., Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev 25 (2007), 357–374.
28. 28 Montalescot, G., Bolognese, L., Dudek, D., et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med 369 (2013), 999–1010.
29. 29 Benjamin, M.M., Filardo, G., Donsky, M.S., Schussler, J.M., A pilot study of prasugrel followed by post-procedural maintenance with clopidogrel in patients receiving percutaneous coronary intervention. J Interv Cardiol 26 (2013), 38–42.
30. 30 Benjamin, M.M., McMaster, K.S., Stoler, R.C., Schussler, J.M., Thirty-day safety and efficacy of prasugrel versus clopidogrel in patients undergoing percutaneous coronary intervention for non-urgent indications and anticoagulated with bivalirudin. IJC Metab Endocr 2 (2014), 26–29.
31. 31 Diodati, J.G., Saucedo, J.F., French, J.K., et al. Effect on platelet reactivity from a prasugrel loading dose after a clopidogrel loading dose compared with a prasugrel loading dose alone: Transferring From Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients (TRIPLET): a randomized controlled trial. Circ Cardiovasc Interv 6 (2013), 567–574.
32. 32 Rollini, F., Franchi, F., Tello-Montoliu, A., et al. Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients. J Am Coll Cardiol Intv 7 (2014), 426–434.
33. 33 Schneider, D.J., Seecheran, N., Raza, S.S., Keating, F.K., Gogo, P., Pharmacodynamic effects during the transition between cangrelor and prasugrel. Coron Artery Dis 26 (2015), 42–48.
34. 34 Dovlatova, N.L., Jakubowski, J.A., Sugidachi, A., Heptinstall, S., The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. J Thromb Haemost 6 (2008), 1153–1159.
35. 35 Steinhubl, S.R., Oh, J.J., Oestreich, J.H., Ferraris, S., Charnigo, R., Akers, W.S., Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb Res 121 (2008), 527–534.
36. 36 Schneider, D.J., Agarwal, Z., Seecheran, N., Keating, F.K., Gogo, P., Pharmacodynamic effects during the transition between cangrelor and ticagrelor. J Am Coll Cardiol Intv 7 (2014), 435–442.
37. 37 Gurbel, P.A., Bliden, K.P., Butler, K., et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 120 (2009), 2577–2585.
38. 38 Angiolillo, D.J., Curzen, N., Gurbel, P., et al. Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: results of the SWAP-2 Study (Switching Anti Platelet-2). J Am Coll Cardiol 63 (2014), 1500–1509.
39. 39 Wiviott, S.D., Trenk, D., Frelinger, A.L., et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 116 (2007), 2923–2932.